ClinicalTrials.gg
CompletedNCT01096186Updated Nov 8, 2019Results posted

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

A Phase 3 interventional study of IPX066 95 mg and IPX066 145 mg in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 81 sites in 10 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
2nd of 14
617 · median 77
Started
2010
with 1 other
Phase 3
7 of 14
none open now
Registered
7th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 2nd largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 7th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.

Read the detailed description

IPX066 is intended for chronic treatment of motor symptoms for all stages of PD. This study is designed to enroll subjects who have successfully completed one of the following studies of IPX066:

  • IPX066-B08-05 (A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease)
  • IPX066-B08-11 (A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa - Levodopa)
  • IPX066-B09-02 (A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced Parkinson's Disease)

All participants will be given IPX066 for 9 months.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • motor Symptoms
  • efficacy
  • IPX066
  • Parkinson's Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each subject must meet the following inclusion criteria in order to be enrolled in the study:

    1. Successful completion of studies IPX066-B08-05, IPX066-B08-11, or IPX066-B09-02.
    2. In the opinion of the Investigator, the Parkinson's disease diagnosis is still valid and the subject remains eligible for LD therapy.

Exclusion criteria

Exclusion Criteria:

  • Each subject must be free of the following exclusion criteria in order to be enrolled in the study:

    1. Received an medication other than those from an IPX066 trial within 4 weeks prior to the planned start of treatment.
    2. Anticipates functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) during study participation.
    3. Received within 4 weeks prior to Baseline Visit or planning to take during study participation: nonselective monoamine oxidase (MAO) inhibitors (with the exception of rasagiline).
    4. In the opinion of the Investigator, should not participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
617 participants (actual)

Study arms

  • Other
    Open Label IPX066

    Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.

    Drug: IPX066 95 mg · Drug: IPX066 145 mg · Drug: IPX066 195 mg · Drug: IPX066 245 mg

Interventions

  • DrugIPX066 95 mg

    23.75 - 95 mg CD-LD capsules

    Also known as: CD-LD ER 95 mg

  • DrugIPX066 145 mg

    36.25 - 145 mg CD-LD capsules

    Also known as: CD-LD ER 145 mg

  • DrugIPX066 195 mg

    48.75 - 195 mg CD-LD capsules

    Also known as: CD-LD ER195 mg

  • DrugIPX066 245 mg

    61.25 - 245 mg CD-LD capsules

    Also known as: CD-LD ER 245 mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III

    Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at End of Study. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25

    Time frame: 9 months

Secondary outcomes

  1. Total UPDRS Parts I-IV

    Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living), UPDRS Part III (Motor Examination), and Part IV (Complications of Therapy \[In the past week\]) at End of Study. Includes both scoring by a clinician and a historical report of mental functioning, activities of daily living and complications of therapy in the past week obtained by questioning the patient. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25

    Time frame: 9 months

  2. Patient Global Impression (PGI)

    Satisfaction of IPX066 using Patient Global Impression (PGI) 7-point scale. Patient Global Impression 0-7 - higher value indicates increased improvement from study start

    Time frame: 9 months

07

Results

Posted Mar 3, 2016

Participant flow

Study dates March 25, 2010 through October 19, 2011 Completion of previous trial a requirement

Participant flow — Overall Study
MilestoneIPX066
Started617
Completed567
Not completed50
Withdrew: Adverse event16
Withdrew: Death4
Withdrew: Lack of efficacy4
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject22
Withdrew: Physician decision1
Withdrew: Noncompliance with study drug1

Outcome measures

PrimaryChange From Baseline in the Sum of UPDRS Part II + UPDRS Part III

Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at End of Study. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25

Time frame:
9 months
Reported as:
Mean · units on a scale
Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III
units on a scaleIPX066
Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III26.4 ± 13.3
SecondaryTotal UPDRS Parts I-IV

Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living), UPDRS Part III (Motor Examination), and Part IV (Complications of Therapy \[In the past week\]) at End of Study. Includes both scoring by a clinician and a historical report of mental functioning, activities of daily living and complications of therapy in the past week obtained by questioning the patient. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25

Time frame:
9 months
Reported as:
Mean · units on a scale
Total UPDRS Parts I-IV
units on a scaleIPX066
Total UPDRS Parts I-IV30.5 ± 14.67
SecondaryPatient Global Impression (PGI)

Satisfaction of IPX066 using Patient Global Impression (PGI) 7-point scale. Patient Global Impression 0-7 - higher value indicates increased improvement from study start

Time frame:
9 months
Reported as:
Mean · units on a scale
Patient Global Impression (PGI)
units on a scaleIPX066
Patient Global Impression (PGI)5.4 ± 1.16

Adverse events

Collected over Screening through 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPX066—43/617 (7%)122/617 (19.8%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventIPX066
Femoral neck fractureInjury, poisoning and procedural complications3/617
Atrial fibrillationCardiac disorders2/617
GastritisGastrointestinal disorders2/617
FallInjury, poisoning and procedural complications2/617
HyponatraemiaMetabolism and nutrition disorders2/617
Spinal column stenosisMusculoskeletal and connective tissue disorders2/617
Spinal osteoarthritisMusculoskeletal and connective tissue disorders2/617
Atrioventricular block completeCardiac disorders1/617
Sick sinus syndromeCardiac disorders1/617
Sinus bradycardiaCardiac disorders1/617
Most frequent other events
Most frequent other events
EventIPX066
InsomniaPsychiatric disorders36/617
DyskinesiaNervous system disorders34/617
FallInjury, poisoning and procedural complications33/617
NauseaGastrointestinal disorders32/617

Baseline characteristics

All enrolled subjects

Age, Continuous
Age, Continuous(years)IPX066
Mean64.1 ± 9.23
Sex: Female, Male
Sex: Female, Male(Participants)IPX066
Female234
Male383
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IPX066
Hispanic or Latino20
Not Hispanic or Latino582
Unknown or Not Reported15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IPX066
White608
Black or African American3
Asian3
Other3
Region of Enrollment
Region of Enrollment(participants)IPX066
Canada48
Latvia2
Romania43
United States260
Ukraine165
Poland50
Lithuania18
Germany19
Estonia3
Spain9
08

Study locations

81 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Mohammed Ali Parkinson's Center
    Phoenix, Arizona 85013, United States
  • HOPE Research Institute
    Phoenix, Arizona 85050, United States
  • Clinical Trials Inc.
    Little Rock, Arkansas 72205, United States
  • Coastal Neurological Medical Group
    La Jolla, California 92037, United States
  • Coordinated Clinical Research
    La Jolla, California 92037, United States
  • The Parkinson's Institute
    Sunnyvale, California 94085, United States
  • Collaborative NeuroScience Network, Inc.
    Torrance, California 90502, United States
  • Bradenton Research Center, Inc.
    Bradenton, Florida 34205, United States
  • Sunrise Clinical Research
    Hollywood, Florida 33021, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Charlotte Neurological Services Parkinson's Disease Treatment Center of S.W. Florida
    Port Charlotte, Florida 33980, United States
  • Suncoast Neuroscience Associates, Inc.
    Saint Petersburg, Florida 33713, United States
  • University of South Florida, Parkinson's Disease and Movement Disorders Center
    Tampa, Florida 33603, United States
  • Medical College of Georgia, Movements Disorders Clinic
    Augusta, Georgia 30912, United States
  • Movement Disorder Center at Idaho Elks Rehabilitation Hospital
    Boise, Idaho 83702, United States
  • Northwestern University, Feinberg School of Medicine, Dept. of Neurology
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Iowa Methodist Medical Center
    Des Moines, Iowa 50309, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Quest Research Institute
    Bingham Farms, Michigan 48025, United States
  • Struthers Parkinson's Center
    Golden Valley, Minnesota 55427, United States
  • UMDNJ Robert Wood Johnson Medical Center, Department of Neurology
    New Brunswick, New Jersey 08901, United States
  • Albany Medical College, Parkinson's Disease and Movement Disorders Center
    Albany, New York 12208, United States
  • David L. Kreitzman, MD, P.C.
    Commack, New York 11725, United States
  • Columbia University Neurological Institute
    New York, New York 10032, United States
  • Institute for Human Performance
    Syracuse, New York 13210, United States
  • Duke University Medical Center Movement Disorders Center
    Durham, North Carolina 27707, United States
  • University Neurology, Inc.
    Cincinnati, Ohio 45219, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29401, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9184, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • South Puget Sound Neurology
    Tacoma, Washington 98405, United States
  • Wisconsin Institute for Neurologic and Sleep Disorders
    Milwaukee, Wisconsin 53233, United States
  • London Health Sciences Centre, University Hospital
    London, Ontario N6A 5A5, Canada
  • Parkinson's & Neurodegenerative Disorder Clinic
    Ottawa, Ontario K1G 4G3, Canada
  • Ottawa Hospital Civic Site
    Ottawa, Ontario K1Y 4E9, Canada
  • Quebec Memory & Motor Skills Disorders Clinic
    Quebec, G1R 3X5, Canada
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • West Tallinn Central Hospital,
    Tallinn, 10617, Estonia
  • Praxis für Neurologie und Psychiatrie
    Westerstede, Niedersachsen 26655, Germany
  • Neurozentrm - Praxis fur Neurologie und Psychiatrie
    Berlin, 10437, Germany
  • Neurologiepraxis
    Berlin, 12163, Germany
  • P.Stradina university hospital
    Riga, 1002, Latvia
  • Gailezers hospital
    Riga, Latvia
  • Kaunas Medical University Hospital
    Kaunas, LT-50009, Lithuania
  • Siauliai Regional Hospital
    Siauliai, LT-76231, Lithuania
  • National Centre of Osteoporosis
    Vilnius, LT-01102, Lithuania
  • Vilnius University Emergency Hospital
    Vilnius, LT-04130, Lithuania
  • Vilnius University Hospital Santariskiu klinikos
    Vilnius, LT-08661, Lithuania
  • PALLMED Sp. z o.o.
    Bydgoszcz, Kujawsko-pomorskie 85-796, Poland
  • Wojewódzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego, SPZOZ w Lublinie
    Lublin, Lubelskie 20-718, Poland
  • Krakowska Akademia Neurologii Sp. z o. o.
    Kraków, Malopolskie 31-530, Poland
  • Centrum Leczenia Chorób Cywilizacyjnych Sp. z o. o. S. K. A.
    Warszawa, Mazowieckie 02-777, Poland
  • Gabinet Neurologiczny, Indywidualna Specjalistyczna Praktyka Lekarska
    Mosina, Wielkopoloskie 62-050, Poland
  • Euromedis Sp. z o.o.
    Szczecin, Zachodniopomorskie 70-215, Poland
  • Neuro-Care NZOZ
    Katowice, 40-546, Poland
  • Psychiatry and Neurology Hospital Brasov, Neurology Department
    Brasov, 500123, Romania
  • Neomed Research
    Brasov, 500283, Romania
  • Colentina Clinical Hospital Bucharest, II Neurology Department
    Bucharest, 020125, Romania
  • CFR Clinical Hospital Constanta, Neurology Department
    Constanta, 900123, Romania
  • Clinical Rehabilitation Hospital Iasi, Neurology Department
    Lasi, 700661, Romania
  • County Clinical Emergency Hospital Targu Mures, I Neurology Department
    Targu Mures, 540136, Romania
  • County Clinical Emergency Hospital Targu Mures, II Neurology Department
    Targu Mures, 540136, Romania
  • County Clinical Emergency Hospital Timisoara, Neurology Department
    Timisoara, 300736, Romania
  • Hospital General de Cataluña
    Sant Cugat Del Valles, Barcelona 08195, Spain
  • Clinica Ruber SA
    Madrid, 28006, Spain
  • Department of neurology and neurosurgery of Dnipropetrovsk State Medical Academy based on Dnipropetrovsk regional hospital named after Mechnikov
    Dnipropetrovsk, 49005, Ukraine
  • Department of Psychiatry and Medical Psychology of Donetsk National Medical University
    Donetsk, 83037, Ukraine
  • Department of Neurological Diseases and Medical Genetic of Donetsk National Medical University
    Donetsk, 83099, Ukraine
  • 1st neurology department of Central Clinical Hospital of Ukrzaliznytsya
    Kharkiv, 61058, Ukraine
  • Department of Vascular Pathology of brain of Institute of neurology, psychiatry and narcology of AMS of Ukraine
    Kharkiv, 61068, Ukraine
  • Institute of Neurology, Psychiatry and Narcology of the AMS of Ukraine
    Kharkiv, 61068, Ukraine
  • Neurology department of Lviv regional clinical hospital
    Lviv, 79010, Ukraine
  • Odessa Regional Clinical Hospital, Dept. of Neurosurgery
    Odesa, 65025, Ukraine
  • Neurology department of Medical Dental Academy based on Poltava regional hospital
    Poltava,, 36000, Ukraine
  • Vinnytsia Regional Psycho-Neurological Hospital
    Vinnytsia, 21005, Ukraine
  • Zaporizhzhya State Medical University based at Zaporizhzhya State Clinical Hospital #6
    Zaporizhzhya, 69035, Ukraine
  • Zaporozhye Regional Clinical Hospital
    Zaporozhye, 69600, Ukraine
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 4 years 5 months after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2010
First posted
Mar 31, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results delay requested
Sep 27, 2013
Results first posted
Mar 3, 2016
Last update
Nov 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01096186
Responsible party
Sponsor
First posted
Mar 31, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Mar 3, 2016
Last update
Nov 8, 2019

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion